Members (10 results)
- Actively Sourcing Deals
- 6 Total Closed Deals
Vetrinox Capital Partners is a private investment firm focused on small to medium sized acquisitions. We partner with exceptional companies seeking the next stage of growth. Post acquisition, we work closely with our portfolio companies to drive measurable value for all stakeholders.
Most Recent Transactions
Investor
Jan 2017
Vetrinox Capital Partners
acquired
Premier Equestrian
Investor
May 2015
Vetrinox Capital Partners
acquired
Hunt Country
Investor
May 2005
Vetrinox Capital Partners
invested in
RDS
Investor
Jan 2005
Vetrinox Capital Partners
acquired
Nedamco
I represent a Special Situation Fund focused on middle-market opportunities in the U.S. We specifically are looking for distressed companies which are looking for a solution. We acquire the debt of these companies.We have helped a multitude of businesses address their crippling debt and are now looking to acquire businesses that are considering bankruptcy because they no longer know what to do.
Who we areWe are an entrepreneurial team of HBS, GSB & McKinsey alums with complementary leadership strengths that are primed for continuing the legacy of your business. We welcome new challenges, are biased towards action, and constantly pursue improvement in ourselves and the organizations in which we belong. What we stand forAs stewards of growing business, we practice the following business tenets:Make sound decisions that balance the interests of customers, employees, and business healthRespect, value, and seek out differences of opinion and experienceAct always with accountability and…
Holding company created to acquire operating pharmacies in the New York City metro area with at least $3 mm revenue. Firm principals have over 100 years of experience in finance and healthcare. We seek to acquire equity stakes in companies with growth prospects with a view to assisting them with their continued development managerially and strategically and ultimately securing a realization of our investment through floatation or sale.
MySolv Technologies Corp. is a Western Canadian based private investment firm with a concentration on owning and operating lower middle-market businesses. MySolv's strategic focus is to seek alliances and opportunities that provide solutions and technology for businesses.
The Pearl West Group (PWG) is a boutique family office that acquires small-to-medium sized businesses. PWG invests its own capital and has no pre-conceived investment time horizon. This allows the businesses we own and acquire to plan and execute strategies with a long-term focus and growth perspective. In addition to relying on our deep experience with mergers & acquisitions and with strategy development, we are specialists in online direct marketing channels. We believe tremendous scale and brand affiliation can be achieved online by many businesses.• PWG can move as swiftly as any…
Altrius is a private investment firm focused on small to medium sized acquisitions. We plan to work closely with our portfolio companies to drive measurable value for all stakeholders.
Most Recent Transactions
Investor
Jul 2009
Altrius
acquired
Sylogent
Blue Skies Collective is a small team of entrepreneurs committed to improving the lives of small business owners and employees. We buy exceptional businesses from owners and operate them for the long haul. By investing in people and treating them right, we believe that better financial outcomes are achieved for employees and the business.
The Fayerweather Group, LLC is a boutique investment firm with holdings in real estate, healthcare, and industrial manufacturing. The firm is looking to expand their enterprise, seeking acquisitions in packaging, plastics, and pharmaceutical manufacturing $5-25m revenue.
The proposal is to erect and commission a Green Field Pharmaceutical products manufacturing and sales company in South India (Bangalore).The promoter of the company is an experienced hand in Pharmaceutical Operations and brings ethical and compliant ways of manufacturing and supply of pharmaceutical products.The company is attempting to solve one of the key risks that a global pharmaceutical company might encounter in space of manufacturing compliance and competitive pricing and yet being able to market their products for the unmet patient demand.The Indian Domestic Market is around $14.50…
Complete the Form for Full Directory Access
Source M&A deals, connect with buyers & investors, or hire an M&A advisor via Axial's lower middle market M&A platform.
Your information is safe and will never be shared or sold.
Send a message to company